Episode 32: Fake friends at the FDA, cancer counter-narratives, and biotech's bear turn
Is the next big idea in oncology a bust? What does "successful" mean exactly? And why does Wall Street hate biotech all of a sudden?
Oct 11, 2018•23 min
The Readout Loud
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episodes
Episode 31: Nobel snubs, millenial founders, and a new kind of lightning round
Did the Nobel Prizes go to the right scientists? Why is there so much disdain for biotech's millenial entrepreneurs? And do journalists have a good taste in '80s music?
Oct 04, 2018•24 min
Episode 30: A fish oil epiphany, VC monopolies and ketamine clinics
Was everyone wrong about fish oil? Is venture capital a cartel? And what's with all those ketamine clinics?
Sep 27, 2018•25 min
Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem
Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don't clinical trials look like America?
Sep 20, 2018•25 min
Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping
Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?
Sep 13, 2018•23 min
Episode 27: Live from Boston!
Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.
Sep 06, 2018•26 min
Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer
Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?
Aug 30, 2018•18 min
Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags
Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?
Aug 23, 2018•22 min
Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T
How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?
Aug 16, 2018•24 min
Episode 23: Congressional insider trading, PETA and fake meat, & doctors vs. fund managers
Can insider trading charges derail political campaigns? Should you trust a fund manager over a doctor? And how many rats would you trade for a cow?
Aug 09, 2018•21 min
Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest
What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative field of oncology? And veteran biotech journalist Luke Timmerman talks about what it's like to climb Mt. Everest.
Aug 02, 2018•23 min
Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data
What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?
Jul 26, 2018•25 min
Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season
Can drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR? Listen, and all will be explained.
Jul 19, 2018•26 min
Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines'
Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug actually works?
Jul 12, 2018•25 min
Episode 18: Biotech's six-month review, how to become a day trader and soul-searching analysts
Adam and Damian recap the past six months in biotech. Investor and philanthropist, Sheff Station, stops by and gives tips on how to become a day trader, and analysts questioning their very existence.
Jul 05, 2018•20 min
Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China
How did the FDA become so friendly to the drug industry? The thorny issue of using 23andMe to unite families separated at the border, and Rebecca explains how drugs are priced in China.
Jun 28, 2018•23 min
Episode 16: Sarepta's big week, Theranos' legal woes and parsing AI hype
Is Sarepta Therapeutics worth $10 billion? Will Theranos' Elizabeth Holmes go behind bars? And how does AI fit into biotech?
Jun 21, 2018•26 min
Episode 15: Problematic parties, Nitpicking NASH, and an opioid documentary from STAT
The problem with the topless dancers at PABNAB. Are investors overestimating the market for fatty liver drugs? And how many lives do biotech entrepreneurs get?
Jun 14, 2018•24 min
Episode 14: Twitter vitriol, biotech jargon, and the plight of the CEO
Why is Twitter so mean to Axovant? Adam teaches a crash course on biostatistics. And will sci-fi gene and cell therapies ever go mainstream.
Jun 07, 2018•27 min
Episode 13: Spending millions on fatty liver disease. Overhyped cancer drugs. Who goes to BIO?
Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?
May 31, 2018•23 min
Episode 12: Ebola should worry you, again; 23andMe's World Cup whoops; Don't drink sunscreen
How worried should you be about Ebola? Can the government lower drug prices without hurting the drug industry? And is socceromics a thing? Listen this week to find out.
May 24, 2018•28 min
Episode 11: Inside the Theranos collapse, Valeant's latest legal lumps, and a few biotech hot takes
What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?
May 17, 2018•23 min
Episode #10: Cohen, Trump, Novartis, oh my; Spark + Amish; Genetic testing at your doc's office?
On today's show, we dig into the no good, very bad day Novartis had when the world got wind of its ties to President Trump's personal attorney, a discussion of how the world's biggest cancer conference used to be the Wild West for investors, and an exploration of one health system's plan to bring genomics to the masses. Also STAT's Eric Boodman joins us to talk about how a pricey new gene therapy has created a fascinating situation in Amish country.
May 10, 2018•22 min
Episode #9 - Bill Gates on deadly flu, Chinese biotech bubbles, Golden State killer genetics
We talk to Bill Gates about the flu that could kill millions. Is China too enamored with biotech startups? And how do you find a cold case killer? Genetics.
May 03, 2018•28 min
Episode #8 - Megamergers, migraines, and biotech's Four Horsemen
What's a good use of $64 billion? Is Big Biotech boring now? And what's the best way to sell hair restoration products to men?
Apr 26, 2018•25 min
Episode #7 - Coke and Pepsi of lung cancer, a debatable drug price, and a cure for capitalism
Is Bristol-Myers Squibb into self-sabotage? Is Congress coming for Gut Guy? And why does Goldman Sachs love money so much?
Apr 19, 2018•22 min
Episode #6 - Biotech buyouts, CEO breakups, and The Rock does CRISPR
Why are biotech investors suddenly so exuberant? What does it mean when a CEO scrubs his LinkedIn profile? And can CRISPR turn your dog into a winged hellhound bent on destroying Chicago?
Apr 12, 2018•24 min
Episode #5 - The FDA's cold shoulder, the latest CAR-T contender, and BuzzFeed's scoop on Grindr
What's it like to be a biotech investor? Do you know where your genetic data are? And what does it mean when the FDA swipes left on your drug?
Apr 05, 2018•23 min
Episode #4 - Mr. Drug CEO doesn't go to DC, billionaires fighting drug prices, a biotech report card
Why aren't pharma CEOs getting hauled into Congress? Which biotech companies got a failing grade this quarter? And why is there no Kelley Blue Book for the price tag of a medicine?
Mar 29, 2018•24 min
Episode #3 - A gene therapy story, breaking down Incyte’s future, and was Gottlieb wrong to try?
What’s it like to watch gene therapy happen? Is the next big cancer clinical trial going to work? And is “right to try” going to defang the FDA?
Mar 22, 2018•25 min
Hosted on Megaphone by Spotify
For the best experience, listen in Metacast app for iOS or Android